Microbiome

If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...

Researchers are exploring whether transferring younger gut microbiomes could slow aging and prevent age-related diseases. If validated, the work could point to microbiome-based therapies that affect systemic health,...

This study suggests brain glymphatic function — a fluid-clearance system — may be altered in people with Crohn’s disease and could relate to inflammation and common neuropsychiatric symptoms like fatigue, anxiety,...

People with IBD may be interested because probiotics are being explored as a safer, non-immunosuppressive approach to help modulate gut microbiota and reduce inflammation, but effective oral delivery remains a key...

This research suggests a new, preclinical microbiome- and metabolite-based pathway (APA-1 → THDCA → TGR5/cAMP/PKA → NLRP3) that reduced inflammation in a mouse model of ulcerative colitis, which could guide future...

If confirmed, the results suggest early-life exposures that perturb the gut microbiome may influence later risk of spondyloarthritis, which could be relevant for parents and clinicians weighing risks and benefits of...

The review links gut microbiota changes and mucosal immune responses across IBD and IgA nephropathy, suggesting that gut dysbiosis may contribute to systemic immune-driven disease.

This review may help patients and clinicians understand how long-lasting changes in bacterial metabolism could contribute to IBD relapse and point toward future microbiome-targeted therapies aimed at restoring resilient...

The study describes a microbiota-responsive cytotoxic CD4+ T‑cell state that associates with worse mucosal inflammation and reduced response to common biologic therapies in ulcerative colitis, suggesting a possible...

This work explores a novel, programmable way to deliver anti-inflammatory protein therapy (IL-10) directly in the gut using engineered yeast and wearable electronics. If further developed and translated, it could offer a...

Vitamin D appears linked to immune regulation, gut barrier health, and the microbiome—processes relevant to IBD and other intestinal disorders. Understanding this could affect how clinicians monitor and study vitamin D...

This animal study suggests Antarctic krill oil may reduce inflammation and weight loss in a mouse model of ulcerative colitis and works alongside changes in gut microbiota and metabolites—findings that could inform...

This paper offers a multi-layered ecological perspective on UC-associated microbiome changes that could help researchers identify which microbial functions or taxa are driven more by random processes versus selection in...

GLP-1 receptor agonists — drugs commonly used to treat obesity and metabolic disease — may help patients with IBD by reducing visceral fat and improving cardiometabolic health.

Understanding how the gut virome shapes regulatory T cells could reveal new biomarkers or therapeutic targets for IBD and related systemic immune diseases. This may help explain unexplained flares or individual...

The study suggests a rice bran extract might reduce colitis severity in rats by shifting gut microbiota and dampening TLR4/NF-κB–driven inflammation, a pathway relevant to human IBD research.

Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.

Identifies gene and microbiome patterns linked to progression from inflammation to irreversible bowel fibrosis in Crohn’s disease, which could eventually help predict who is at higher risk and inform prevention...

This study suggests that specific gut bacteria targeted by systemic IgG are associated with UC activity and inflammation, which could eventually help identify microbial signals linked to flares or systemic inflammation.

Fibrosis (irreversible bowel scarring) is a major cause of surgery in Crohn’s disease. This study points to molecular and microbiome patterns that may help predict or distinguish fibrosis from active inflammation, which...

Fibrosis (irreversible bowel scarring) is a major cause of surgery in Crohn’s disease. Identifying molecular and microbial markers tied to fibrosis could eventually help predict who’s at higher risk and guide earlier,...

The work points to measurable molecular and microbial patterns that may help distinguish treatable inflammation from progressive fibrosis and suggests AI could aid in building predictive tools from limited samples —...

This study presents a targeted immunotherapy approach designed to concentrate an immune‑modulating protein (PD‑L1‑Fc) in the inflamed colon, which could in future reduce systemic side effects of biologic immunomodulators...

The study tests whether combining a standardized coping-skills program with biologic therapy improves emotional well-being and clinical/endoscopic outcomes in people with early Crohn's disease—addressing common...

AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...

The paper describes a preclinical demonstration that a plant-derived compound reduced inflammation and changed gut microbiota and metabolite profiles in a mouse colitis model, suggesting a possible route for future...

The study suggests a probiotic strain (Lactobacillus plantarum) reduced inflammation and prolonged remission in multiple mouse models of Crohn’s-like disease, indicating microbiome-based approaches might be promising to...

Bile acids shaped by gut microbes can influence inflammation and metabolism, so understanding these pathways could lead to new biomarkers or treatments relevant to people with IBD.

New targeted-delivery research could lead to treatments that reduce gut inflammation while also shifting the microbiome — both relevant to IBD management. However, this report is preclinical and does not mean the therapy...

Shared gut microbiome shifts across autoimmune diseases could suggest common microbial factors relevant to immune regulation and might eventually inform diagnostics or therapies relevant to people with IBD.

This study links population-level IBD epidemiology to gut microbiome changes and proposes a microbial risk score that might help detect or surveil IBD patterns. That could inform future biomarker development or...

This review suggests Aloe vera polysaccharides could support gut barrier repair, microbiome balance, and immune regulation—mechanisms relevant to IBD inflammation and healing. However, evidence is mainly preclinical and...

Nanotechnology approaches aim to improve how cytokine-targeting therapies are delivered in IBD, which could reduce systemic exposure and immunogenicity and increase local effectiveness.

Intestinal fibrosis causes strictures that often need surgery and has few effective medical treatments; linking the microbiome to fibrogenesis suggests new prevention or treatment strategies that could reduce surgery...

Researchers found antisense RNA activity in gut microbes that tracks with active inflammation in IBD and with faecal calprotectin — suggesting a new microbial signal that might help understand or monitor disease...

The study describes a novel oral delivery system that both protects stem-cell-derived extracellular vesicles and actively modifies the gut environment, which could point to new microenvironment-targeted IBD therapies.

Faecal microbiota transfer is being tested in a large Phase 3 trial as a possible new treatment approach for active ulcerative colitis, and this study also looks at safety and how the therapy changes the gut microbiome...

This review pools available human and animal studies on sodium butyrate for ulcerative colitis and highlights promising signals—especially for oral microencapsulated formulations—while noting that clinical evidence is...

The study explores a novel, combined nanozyme + microbiome-derived vesicle approach aimed at reducing oxidative stress and modulating inflammation in IBD — mechanisms that are relevant to disease pathways and future...

This review organizes and grades causal evidence linking individual gut bacteria, their metabolites, and host pathways in IBD—helping researchers and clinicians see which microbe–metabolite mechanisms are best supported...

People with UC may be interested because the study identifies a traditional herbal formulation that reduced disease markers in a mouse model and changed gut microbiota and inflammatory pathways (IL‑17), suggesting...

This project seeks to clarify how gut microbes and diet drive CD4+ T cell responses—mechanisms that are central to intestinal tolerance and to diseases like IBD. A better map of TCR–antigen pairs and how tolerance breaks...

Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...

This preclinical study links cod skin–derived collagen peptides to reduced colitis severity in mice through changes in the gut microbiota and suppression of the NLRP3 inflammasome — pathways that could be relevant to...

This study explores a multi-component traditional medicine that the authors report can reduce experimental colitis and modulate inflammatory signaling and the gut microbiome — findings that could guide future preclinical...

People with IBD are often interested in new, less toxic therapies that restore gut health. PEVs are an emerging microbiome-based approach that could one day offer targeted immune and barrier benefits without live...

This study describes a new clay-based nanotherapy that reduced inflammation and oxidative stress in a common mouse model of colitis, suggesting a potential local treatment approach that targets multiple disease...

The study presents a new edible nanoparticle that delivers resveratrol to the colon and improved disease markers in a mouse model of ulcerative colitis, which could inform future delivery strategies for plant-derived...